Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Overview of attention for article published in Health Economics Review, August 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users
facebook: 1 Facebook page

reddit: 1 Redditor

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Facebook Reddit Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,920 followers.

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data https://t.co/Xjj2svjEVQ https://t.co/NwGe4P82k3

28 Aug 2018

Reply Repost Favourite

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data https://t.co/fAtSVOOgww https://t.co/wrsnMbkrEI

28 Aug 2018

Reply Repost Favourite

#HealthEconJA Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data https://t.co/Pt0oMuFGS0

28 Aug 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.